imatinib mesylate has been researched along with Argentaffinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eriksson, B; Eriksson, C; Granberg, D; Gustavsson, B; Janson, ET; Kindmark, H; Kozlowacki, G; Larsson, G; Oberg, K; Skogseid, B; Welin, S | 1 |
| Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R | 1 |
| Abbruzzese, JL; Ajani, JA; Ellis, L; Hess, K; Rashid, A; Szklaruk, J; Xie, K; Yao, JC; Yeung, SC; Zhang, JX | 1 |
2 trial(s) available for imatinib mesylate and Argentaffinoma
| Article | Year |
|---|---|
Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
Topics: Antineoplastic Agents; Benzamides; Carcinoid Tumor; Endocrine Gland Neoplasms; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2010 |
Clinical and in vitro studies of imatinib in advanced carcinoid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoid Tumor; Cell Line, Tumor; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2007 |
1 other study(ies) available for imatinib mesylate and Argentaffinoma
| Article | Year |
|---|---|
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2012 |